<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Basic and Clinical Neuroscience Journal</title>
<title_fa>مجله علوم اعصاب پایه و بالینی</title_fa>
<short_title>BCN</short_title>
<subject>Medical Sciences</subject>
<web_url>http://bcn.iums.ac.ir</web_url>
<journal_hbi_system_id>137</journal_hbi_system_id>
<journal_hbi_system_user>journal137</journal_hbi_system_user>
<journal_id_issn>2008-126X</journal_id_issn>
<journal_id_issn_online>2228-7442</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.32598/bcn</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1396</year>
	<month>12</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2018</year>
	<month>3</month>
	<day>1</day>
</pubdate>
<volume>0</volume>
<number>Accepted Articles</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Nobiletin Attenuates Neurological Deficits, Blood-Brain Barrier Permeability, and Cerebral Edema in a Rat Model of Traumatic Brain Injury: Roles of IL-1 and IL-10</title>
	<subject_fa>Behavioral Neuroscience</subject_fa>
	<subject>Behavioral Neuroscience</subject>
	<content_type_fa>Original</content_type_fa>
	<content_type>Original</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-size:14px;&quot;&gt;&lt;span style=&quot;font-family:Tahoma;&quot;&gt;&lt;span style=&quot;line-height:2;&quot;&gt;&lt;b&gt;Objective&lt;/b&gt;: To test whether nobiletin (NOB) improves neurological and motor function and mitigates secondary injury (edema, BBB disruption, histopathology) via modulation of IL‑1&amp;beta; and IL‑10 in a severe diffuse TBI rat model.&lt;br&gt;
&lt;b&gt;Methods&lt;/b&gt;: Adult male Wistar rats (n=56; 7 groups, 8-10 rats/group) underwent Marmarou weight‑drop TBI or sham/controls: Intact, Sham, TBI, Vehicle/Saline, NOB 25 mg/kg, NOB 50 mg/kg, NOB 100 mg/kg. NOB or vehicle was administered intraperitoneally 30 min post‑injury (single dose; [insert solvent and volume]). Neurological (VCS) and motor (beam walk, balance beam) scores were assessed on Days 0&amp;ndash;3 by blinded evaluators. Brain water content and Evans blue extravasation were measured at 72 h. CSF IL‑1&amp;beta; and IL‑10 were quantified by ELISA. Histology (H&amp;E, 5 &amp;micro;m) was evaluated blinded; [optional] semi‑quantitative neuronal injury scores were assigned. Primary analysis for longitudinal behavior used two‑way repeated‑measures ANOVA; other endpoints used one‑way ANOVA with Tukey&amp;rsquo;s test; data are mean &amp;plusmn; SEM.&lt;br&gt;
&lt;b&gt;Results&lt;/b&gt;: Compared with TBI/Vehicle, NOB 25 and 50 mg/kg improved VCS and motor performance across Days 1&amp;ndash;3 (Group&amp;times;Day interaction [insert F, p]). AUC analyses corroborated these effects. NOB 50 mg/kg most consistently reduced brain water content ([insert % reduction] vs TBI; p=[insert]) and Evans blue permeability ([insert % reduction]; p=[insert]). CSF IL‑1&amp;beta; increased after TBI and was reduced by NOB 25 and 50 mg/kg ([insert values], p=[insert]); IL‑10 decreased after TBI and was increased by NOB 25 and 50 mg/kg ([insert], p=[insert]). The 100 mg/kg dose showed limited or no benefit across endpoints. Histology revealed attenuated neuronal edema/pyknosis and vascular congestion with NOB 25&amp;ndash;50 mg/kg; [if scored] injury scores were reduced vs TBI/Vehicle (p=[insert]).&lt;br&gt;
&lt;b&gt;Conclusion&lt;/b&gt;: A single post‑injury dose of nobiletin at 25&amp;ndash;50 mg/kg improved neurological outcomes and mitigated edema, BBB disruption, histopathology, and cytokine imbalance within 72 h after severe diffuse TBI, with 50 mg/kg showing the most consistent efficacy. The 100 mg/kg dose was not beneficial. Findings support anti‑inflammatory and vasculoprotective actions of nobiletin in acute TBI.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Nobiletin, Traumatic brain injury, Cytokines, IL-1β, IL-10</keyword>
	<start_page>0</start_page>
	<end_page>0</end_page>
	<web_url>http://bcn.iums.ac.ir/browse.php?a_code=A-10-3050-3&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Vahid</first_name>
	<middle_name></middle_name>
	<last_name>Alivirdiloo</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>v.alivirdiloo@gmail.com</email>
	<code>13700319475328460058460</code>
	<orcid>13700319475328460058460</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Ramsar Campus, Mazandaran University of Medical Sciences, Ramsar, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Mobasher</first_name>
	<middle_name></middle_name>
	<last_name>Hajiabbasi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>mobasherhajiabbasi93@gmail.com</email>
	<code>13700319475328460058461</code>
	<orcid>13700319475328460058461</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Islamic Azad University of Tonekabon, Tonekabon, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Ali</first_name>
	<middle_name></middle_name>
	<last_name>Siahposht Khachaki</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>a.siahposht@yahoo.com</email>
	<code>13700319475328460058462</code>
	<orcid>13700319475328460058462</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Immunogenetics Research Center, Departments of Physiology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. </affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Aydin</first_name>
	<middle_name></middle_name>
	<last_name>Sadeghi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>Aidinsadeghy670@gmail.com</email>
	<code>13700319475328460058463</code>
	<orcid>13700319475328460058463</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Amol Campus of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. </affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Saeid</first_name>
	<middle_name></middle_name>
	<last_name>Bagheri-Mohammadi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>bagherimohammadi-sa@sbmu.ac.ir</email>
	<code>13700319475328460058464</code>
	<orcid>13700319475328460058464</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Immunogenetics Research Center, Mazandaran University of Medical Sciences, Sari, Iran. </affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
